银杏内酯注射液治疗进展性缺血性卒中患者的效果

Effects of Ginkgolides injection in treatment of patients with progressive ischemic stroke

目的:观察银杏内酯注射液治疗进展性缺血性卒中患者的效果。方法:回顾性分析2019年5月至2021年5月该院收治的78例进展性缺血性卒中患者的临床资料,按治疗方法不同将其分成对照组与研究组各39例。对照组采用常规治疗,研究组在对照组基础上联合银杏内酯注射液治疗,比较两组治疗前后神经功能缺损程度[美国国立卫生研究院卒中量表(NIHSS)]评分、临床疗效、疾病相关指标[C反应蛋白(CRP)、神经元特异性烯醇化酶(NSE)、血管内皮生长因子(VEGF)、同型半胱氨酸(Hcy)]水平和不良反应发生率。结果:治疗7、14 d后,两组NIHSS评分均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);研究组治疗总有效率为92.31%(36/39),高于对照组的71.79%(28/39),差异有统计学意义(P<0.05);治疗后,两组CRP、NSE、VEGF、Hcy水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:在常规治疗基础上采用银杏内酯注射液治疗进展性缺血性卒中患者可提高治疗总有效率,降低NIHSS评分和疾病相关指标水平,其效果优于单纯常规治疗。

Objective: To observe effects of Ginkgolides injection in treatment of patients with progressive ischemic stroke. Methods: The clinical data of 78 patients with progressive ischemic stroke admitted to this hospital from May 2019 to May 2021 were retrospectively analyzed.They were divided into control group and study group according to different treatment methods, 39 cases in each group. The control group was treated with conventional therapy, while the study group was treated with Ginkgolides injection on the basis of that of the control group. The degree of neurological deficit [national institutes of health stroke scale(NIHSS)] score, the clinical efficacy, the disease-related indicator levels [C-reactive protein(CRP), neuron-specific enolase(NSE), vascular endothelial growth factor(VEGF), homocysteine(Hcy)], and incidence of adverse reactions were compared before and after the treatment. Results: After 7 and 14 days of treatment, the NIHSS scores of the two groups were lower than those before the treatment, those of the study group were lower than those of the control group, and the differences were statistically significant(P<0.05). The total effective rate of treatment in the study group was 92.31%(36/39), which was higher than 71.79%(28/39) in the control group, and the difference was statistically significant(P<0.05). After the treatment, the levels of CRP, NSE, VEGF and Hcy in the two groups were lower than those before the treatment, those in the study group were lower than those in the control group, and the differences were statistically significant(P<0.05). However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusions: On the basis of conventional treatment, Ginkgolides injection in the treatment of the patients with progressive ischemic stroke can improve the total effective rate, and reduce the NIHSS scores and the disease related indicator levels. Moreover, it is superior to single conventional therapy.